Advances in Cancer Research

Erscheinungsjahr 2019
ISBN: 978-0-12-817153-0
Verlag: ACADEMIC PR INC

Buch, Englisch, Band 142, 217 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 463 g

Reihe: Advances in Cancer Research

Advances in Cancer Research, Volume 142, the latest release in this ongoing, well-regarded serial, provides invaluable information on the exciting and fast-moving field of cancer research.

Zielgruppe

<p>Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.</p>

Autoren/Hrsg.

Fisher, Paul B.

Tew, Kenneth D.

Weitere Mitwirkende

Tew, Kenneth D.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

1. Highly variant DNA methylation in normal tissues identifies a distinct subclass of cancer patientsJayashri Ghosh, Bryant Schultz, Christos Coutifaris and Carmen Sapienza2. Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylationsRyan M. Phillips, Christine Lam, Hailun Wang and Phuoc T. Tran3. The second genome: Effects of the mitochondrial genome on cancer progressionAdam D. Scheid, Thomas C. Beadnell and Danny R. Welch4. Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumorsManny D. Bacolod, Francis Barany, Karsten Pilones, Paul B. Fisher and Romulo J. de Castro5. HVEM network signaling in cancerJohn R. Sedý and Parham Ramezani-Rad6. Pharmacology of ME-344, a novel cytotoxic isoflavoneLeilei Zhang, Jie Zhang, Zhiwei Ye, Danyelle M. Townsend and Kenneth D. Tew

Über Autor(innen)

Tew, Kenneth D.
Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA
The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.